GovChime
Notice ID: 16f0d3a0ac4244809319904e2656f3c7PresolicitationArchived

Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression

Archived on March 1, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
1:00 PM EST
Posted
January 30, 2026
Notice type
Presolicitation
Set-aside
No Set aside used
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Department of Health and Human ServicesOFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION (ASA)

Notice details

Office
PROGRAM SUPPORT CENTER ACQ MGMT SVC
Place of performance
Philadelphia, Pennsylvania, 19104
Last updated
Nov 3, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
NIH-26-006363-IntentNotice
Notice ID
16f0d3a0ac4244809319904e2656f3c7

Description

This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only. 

Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update.

------------------------------------------------------------------------------------------------------------------------

The intent is to award a contract on a solesource basis for Nucleic acid–based reagents for in vivo transient protein expression for the National Cancer Institute and Center for Cancer Research to: 

Trustees of The University of Pennsilvania - Penn Medicine

3451 Walnut Street

Philadelphia, PA

19104, USA

The supplies required are nucleic acid-based reagents. 

The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models. The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models.

Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models. Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier  for these reagents in order to ensure consistency with materials used in previous preclinical studies. These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

  1. 1
    Version 1PresolicitationArchived

    Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression

    Notice e3675be32c5f47f3801816ac68017a33 on SAM.gov

  2. 3
    Version 3PresolicitationArchivedCurrent

    Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression

    Notice 16f0d3a0ac4244809319904e2656f3c7 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

NIH-26-006363-IntentNotice

Archive Date

Mar 1, 2026

Office Address

ROCKVILLE, MD, 20857